Cargando…

High Prevalence of the K65R Mutation in HIV-1 Subtype C Infected Patients Failing Tenofovir-Based First-Line Regimens in South Africa

BACKGROUND: Tenofovir (TDF) has replaced stavudine (d4T) as the preferred nucleoside reverse transcriptase inhibitor (NRTI) in first-line regimens in South Africa, but limited information is available on the resistance patterns that develop after the introduction of TDF. This study investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skhosana, Lindiwe, Steegen, Kim, Bronze, Michelle, Lukhwareni, Azwidowi, Letsoalo, Esrom, Papathanasopoulos, Maria A., Carmona, Sergio C., Stevens, Wendy S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320083/ https://www.ncbi.nlm.nih.gov/pubmed/25659108 http://dx.doi.org/10.1371/journal.pone.0118145

Ejemplares similares

High-Level Cross-Resistance to Didanosine Observed in South African Children Failing an Abacavir- or Stavudine-Based 1(st)-Line Regimen
por: Steegen, Kim, et al.
Publicado: (2014)

Resistance in Patients Failing Integrase Strand Transfer Inhibitors: A Call to Replace Raltegravir With Dolutegravir in Third-Line Treatment in South Africa
por: Steegen, Kim, et al.
Publicado: (2019)

Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey
por: Steegen, Kim, et al.
Publicado: (2016)

HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone
por: Bronze, Michelle, et al.
Publicado: (2012)

Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment
por: Steegen, Kim, et al.
Publicado: (2022)

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration
por: Rhee, Soo-Yon, et al.
Publicado: (2017)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans
por: Lukhwareni, Azwidowi, et al.
Publicado: (2020)

No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom
por: White, Ellen, et al.
Publicado: (2016)

Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide
por: Hung, Anna, et al.
Publicado: (2020)

Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa
por: Brennan, Alana T, et al.
Publicado: (2013)

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa
por: Wallis, Carole L., et al.
Publicado: (2011)

Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen
por: Darnell, Julia, et al.
Publicado: (2021)

K65R in Subtype C HIV-1 Isolates from Patients Failing on a First-Line Regimen Including d4T or AZT: Comparison of Sanger and UDP Sequencing Data
por: Recordon-Pinson, Patricia, et al.
Publicado: (2012)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
por: Wang, Huilian, et al.
Publicado: (2016)

Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya
por: Karoney, Mercy Jelagat, et al.
Publicado: (2022)

Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis
por: Chan, Philip A, et al.
Publicado: (2012)

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
por: Chua, Arlene C, et al.
Publicado: (2012)

Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
por: Plum, Pierre-Emmanuel, et al.
Publicado: (2021)

Drug-susceptibility Patterns of Mycobacterium tuberculosis in Mpumalanga Province, South Africa: Possible Guiding Design of Retreatment Regimen
por: Green, E., et al.
Publicado: (2010)

Tracking the Antigenic Evolution of Foot-and-Mouth Disease Virus
por: Reeve, Richard, et al.
Publicado: (2016)

Delayed onset renal failure in a patient on tenofovir based antiretroviral regimen
por: Krishna, M. Murali, et al.
Publicado: (2014)

Viral Blips Were Infrequent in HIV-1-Infected Virologically-Suppressed Adults Treated with Tenofovir Alafenamide or Tenofovir DF Rilpivirine-Containing Regimens
por: Wohl, David A, et al.
Publicado: (2017)

1014. Factors Associated with Switching from Tenofovir Diproxil Phosphate to a Tenofovir Alafenamide Based Regimen in a Cohort with Unrestricted Access to Care and Medications
por: Ganesan, Anuradha, et al.
Publicado: (2020)

Efficacy and Tolerability of Tenofovir Disoproxil Fumarate Based Regimen as Compared to Zidovudine Based Regimens: A Systematic Review and Meta-Analysis
por: Dadi, Tegene Legese, et al.
Publicado: (2017)

HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug Resistance
por: Günthard, Huldrych F., et al.
Publicado: (2016)

High Tenofovir Failure Rates in an Emerging, Non-B Subtype HIV Epidemic
por: Salvana, Edsel Maurice, et al.
Publicado: (2017)

Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment
por: Kozielewicz, Dorota, et al.
Publicado: (2015)

A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences
por: Steegen, Kim, et al.
Publicado: (2010)

HIV Disclosure to Partners and Family among Women Enrolled in Prevention of Mother to Child Transmission of HIV Program: Implications for Infant Feeding in Poor Resourced Communities in South Africa
por: Madiba, Sphiwe, et al.
Publicado: (2013)

Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda
por: Ayitewala, Alisen, et al.
Publicado: (2020)

Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports
por: Fox, Julie, et al.
Publicado: (2016)

HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana †
por: Seatla, Kaelo K., et al.
Publicado: (2021)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Immunogenicity of native and CD4 liganded monomeric and trimeric envelope glycoproteins based on HIV-1 Subtype C consensus Founder virus sequences
por: Killick, MA, et al.
Publicado: (2012)

Lack of utility of phosphate serum monitoring in HIV-infected patients on a tenofovir-based antiretroviral regimen
por: Wikman, P, et al.
Publicado: (2010)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
por: Jayakumar, Rajeswari, et al.
Publicado: (2012)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levels
por: Kelly Pillay, Sameshnee, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_q1ah356vqrhc1uulhdroanjtr9